What is Actoplus Met?
Actoplus Met is Takeda’s tablet combining pioglitazone, a thiazolidinedione that makes tissues more sensitive to insulin, with metformin, a biguanide, to improve blood sugar control alongside diet and exercise in adults with type 2 diabetes. It is not for type 1 diabetes or diabetic ketoacidosis. It carries two boxed warnings: pioglitazone can cause or worsen heart failure, and metformin can rarely cause fatal lactic acidosis. It is contraindicated in serious heart failure, severe kidney impairment and metabolic acidosis.1
Approved products and generic therapeutic-equivalence ratings are listed in the FDA Orange Book.3
The two ingredients work differently: pioglitazone activates the PPAR-gamma receptor to improve insulin sensitivity in muscle, fat and liver, while metformin reduces glucose production by the liver and its absorption from the gut.1
In a 24-week trial of 600 adults on diet and exercise alone, the combination lowered HbA1c by 1.8 points, versus 1.0 with either drug alone, and 64% reached an HbA1c of 7% or less.1
Pioglitazone causes fluid retention, which explains the dose-related ankle swelling and weight gain seen in trials and the heart-failure warning.
Because pioglitazone can restore ovulation in some women who are not ovulating, the possibility of unintended pregnancy is discussed before treatment.
Actoplus Met is one of the diabetes medicines; Duetact pairs pioglitazone with glimepiride instead.
